Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBO
2023-505809-17-00Phase 3Withdrawn
- Sponsor
- E-Pharma Trento
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ibuprofen + acetylcysteine and ibuprofen in upper respiratory infection (URI) (3 arms), sponsored by E-Pharma Trento. Primary endpoint: Time to clinically significant improvement of URTI signs and symptoms. Planned start Nov 2023; status: withdrawn.
02
Drugs
ibuprofen + acetylcysteineibuprofen
03
Conditions
upper respiratory infection (URI)
Beyond the preview
Go deeper on 2023-505809-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505809-17-00.